CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.


Journal

Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937

Informations de publication

Date de publication:
22 08 2019
Historique:
received: 07 05 2019
accepted: 12 08 2019
entrez: 24 8 2019
pubmed: 24 8 2019
medline: 1 8 2020
Statut: epublish

Résumé

We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.

Identifiants

pubmed: 31439003
doi: 10.1186/s13045-019-0771-0
pii: 10.1186/s13045-019-0771-0
pmc: PMC6704571
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Antineoplastic Agents, Immunological 0
CD33 protein, human 0
Immunoconjugates 0
Sialic Acid Binding Ig-like Lectin 3 0
lintuzumab V00Y10W60W

Types de publication

Letter Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

85

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA230319
Pays : United States

Références

Blood. 2007 May 15;109(10):4168-70
pubmed: 17227830
Lancet Oncol. 2014 Aug;15(9):986-96
pubmed: 25008258
Ann Hematol. 2015 Mar;94(3):361-73
pubmed: 25284166
Expert Rev Hematol. 2016;9(4):335-50
pubmed: 26778118
J Clin Oncol. 2016 Mar 1;34(7):747-55
pubmed: 26786921
Blood. 2016 Apr 28;127(17):2157-60
pubmed: 26929274
Leukemia. 2017 May;31(5):1059-1068
pubmed: 27795558
J Clin Oncol. 2017 Aug 10;35(23):2674-2682
pubmed: 28644774
Blood. 2018 Jan 25;131(4):468-471
pubmed: 29229596
Expert Opin Investig Drugs. 2018 Apr;27(4):339-348
pubmed: 29534618

Auteurs

Michele Stanchina (M)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Alessandro Pastore (A)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Sean Devlin (S)

Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Christopher Famulare (C)

Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Eytan Stein (E)

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

Justin Taylor (J)

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. taylorj7@mskcc.org.
Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. taylorj7@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH